{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Risperidone+Long+Acting", "query": { "intervention": "Risperidone Long Acting" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Risperidone+Long+Acting&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T13:12:49.244Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01411085", "title": "Risperidone and Desipramine in Alcohol Use and Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia", "Alcoholism", "Dual Diagnosis" ], "interventions": [ { "name": "Risperidone + Desipramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2011-12", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2018-03-23", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 4, "location_summary": "Worcester, Massachusetts • Grand Rapids, Michigan • Lebanon, New Hampshire + 1 more", "locations": [ { "city": "Worcester", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Columbia", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01411085" }, { "nct_id": "NCT02087579", "title": "Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psychotic Disorders", "Schizophrenia", "Bipolar Disorder", "Depressive Disorder" ], "interventions": [ { "name": "Aripiprazole, oral formulation", "type": "DRUG" }, { "name": "Olanzapine, oral formulation", "type": "DRUG" }, { "name": "Paliperidone, oral formulation", "type": "DRUG" }, { "name": "Paliperidone, LAI", "type": "DRUG" }, { "name": "Quetiapine, oral formulation", "type": "DRUG" }, { "name": "Risperidone, oral formulation", "type": "DRUG" }, { "name": "Risperidone, LAI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 305, "start_date": "2014-02", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-10-29", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 6, "location_summary": "Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hoffman Estates", "state": "Illinois" }, { "city": "Cedarhurst", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02087579" }, { "nct_id": "NCT00330551", "title": "Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Oral Risperidone", "type": "DRUG" }, { "name": "Risperidone in Long-Acting Injectable Form (Consta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 126, "start_date": "2006-03", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00330551" }, { "nct_id": "NCT00330863", "title": "Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Risperidone microspheres", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 357, "start_date": "2006-05", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2018-07-10", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 8, "location_summary": "Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Fall River", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00330863" }, { "nct_id": "NCT02431702", "title": "A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia", "Psychotic Disorders" ], "interventions": [ { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Oral Paliperidone ER", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Oral Risperidone", "type": "DRUG" }, { "name": "Paliperidone Palmitate Injection (PP1M)", "type": "DRUG" }, { "name": "Paliperidone Palmitate Injection (PP3M)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 337, "start_date": "2015-07-08", "completion_date": "2019-11-12", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 34, "location_summary": "Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431702" }, { "nct_id": "NCT05179525", "title": "Comparative Bioavailability of Risperidone.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Risperidone ISM® 100 mg", "type": "DRUG" }, { "name": "Risperdal 4mg Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rovi Pharmaceuticals Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 80, "start_date": "2021-03-09", "completion_date": "2021-09-17", "has_results": false, "last_update_posted_date": "2022-01-05", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 4, "location_summary": "Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Gaithersburg", "state": "Maryland" }, { "city": "Berlin", "state": "New Jersey" }, { "city": "DeSoto", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05179525" }, { "nct_id": "NCT00287027", "title": "Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Psychotic Disorders" ], "interventions": [ { "name": "Risperdal Long Acting Injectable Antipsychotic Medication", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Alliance on Mental Illness New Hampshire", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2006-02", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2007-01-05", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 1, "location_summary": "Concord, New Hampshire", "locations": [ { "city": "Concord", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287027" }, { "nct_id": "NCT01451736", "title": "Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia (Recent-onset)" ], "interventions": [ { "name": "paliperidone palmitate", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 146, "start_date": "2011-10", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2022-04-11", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01451736" }, { "nct_id": "NCT00246194", "title": "Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "risperidone (RISPERDAL CONSTA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen, LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 532, "start_date": "2004-09", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2014-04-04", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246194" }, { "nct_id": "NCT00821600", "title": "Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psychotic Disorders", "Schizophrenia" ], "interventions": [ { "name": "risperidone IR and LAI formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2008-12", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2014-05-21", "last_synced_at": "2026-09-25T13:12:49.244Z", "location_count": 3, "location_summary": "Cerritos, California • Santa Ana, California • Atlanta, Georgia", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00821600" } ] }